Is the acute NMDA receptor hypofunction a valid model of schizophrenia?

Schizophrenia Bulletin

Volumn 38, Issue 1, 2012, Pages 9-14

  Adell, Albert ^a,b   Jiménez Sánchez, Laura ^a,b   López Gil, Xavier ^a,b   Romón, Tamara ^a,b  

^a INST D INVESTIGACIONS B   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

antipsychotics; ketamine; MK 801; phencyclidine

Indexed keywords

DIZOCILPINE; GLUTAMATE DECARBOXYLASE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PARVALBUMIN; PHENCYCLIDINE;

ARTICLE; CONSTRUCT VALIDITY; DISEASE MARKER; FACE VALIDITY; NERVE CELL DIFFERENTIATION; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY GATING; STEREOTYPY; TREATMENT RESPONSE;

ANIMALS; CORPUS CALLOSUM; DISEASE MODELS, ANIMAL; DOPAMINE; GLUTAMIC ACID; HUMANS; KETAMINE; PARVALBUMINS; PHENCYCLIDINE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, N-METHYL-D-ASPARTATE; RODENTIA; SCHIZOPHRENIA; SEROTONIN;

EID: 84555195003     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr133     Document Type: Article

References (30)

1. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry. 1959;81:363-369.
2. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
3. Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci. 1996;16:19-30. (Pubitemid 26010694)
4. Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry. 2006;11:118-119. (Pubitemid 43164609)
5. Stone JM, Erlandsson K, Arstad E, et al. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [123I]CNS-1261 SPET study. Psychopharmacology (Berl). 2008;197:401-408.
6. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20:201-225. (Pubitemid 29067401)
7. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001;156:234-258. (Pubitemid 32705488)
8. Shelley AM, Silipo G, Javitt DC. Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction. Schizophr Res. 1999;37:65-79. (Pubitemid 29167027)
9. Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry. 2002;51:400-406. (Pubitemid 34251177)
10. Duncan EJ, Madonick SH, Parwani A, et al. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology. 2001;25:72-83. (Pubitemid 32493823)
11. Javitt DC, Steinschneider M, Schroeder CE, Arezzo JC. Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci USA. 1996;93:11962-11967. (Pubitemid 26347231)
12. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349-1352. (Pubitemid 28406826)
13. López-Gil X, Babot Z, Amargós-Bosch M, Suñol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology. 2007;32:2087-2097. (Pubitemid 47417703)
14. Callicott JH, Bertolino A, Mattay VS, et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex. 2000;10:1078-1092.
15. Manoach DS, Gollub RL, Benson ES, et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry. 2000;48:99-109. (Pubitemid 30618799)
16. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 1995;6:869-872.
17. Vollenweider FX, Vontobel P, Oye I, Leenders KL, Hell D. Effects of S-ketamine on striatal dopamine release: a [11C] raclopride PET study of a model psychosis in humans. J Psychiatr Res. 2000;34:35-43. (Pubitemid 30006939)
18. Ngan ET, Yatham LN, Ruth TJ, Liddle PF. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [18F]setoperone. Am J Psychiatry. 2000;157:1016-1018. (Pubitemid 30412359)
19. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998-1007.
20. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007;318:1645-1647. (Pubitemid 350233667)
21. Enomoto T, Tse MT, Floresco SB. Reducing prefrontal gamma-aminobutyric acid activity induces cognitive, behavioral, and dopaminergic abnormalities that resemble schizophrenia. Biol Psychiatry. 2011;69:432-441.
22. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005;6:312-324. (Pubitemid 40469985)
23. Romón T, Mengod G, Adell A. Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia. Psychopharmacology (Berl). 2011;217:231-238.
24. Innocenti GM, Ansermet F, Parnas J. Schizophrenia, neurodevelopment and corpus callosum. Mol Psychiatry. 2003;8:261-274. (Pubitemid 36712920)
25. Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry. 2004;161:882-888. (Pubitemid 38625342)
26. Liao Y, Tang J, Mingdong M, et al. Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain. 2010;133:2115-2122.
27. López-Gil X, Jiménez-Sánchez L, Romón T, Campa L, Artigas F, Adell A. Importance of interhemispheric prefrontal connection in the effects of noncompetitive NMDA receptor antagonists. Int J Neuropsychopharmacol. In press. doi:10.1017/S1461145711001064.
28. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev. 2008;60:358-403.
29. Patil ST, Zhang L, Martenyi F. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102-1107. (Pubitemid 47517511)
30. López-Gil X, Artigas F, Adell A. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Curr Pharm Des. 2010;16:502-515.